Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 13/20 | 0.65 |
| ▸ | CDK1 | P06493 | 12/20 | 0.65 |
| ▸ | CCND1 | P24385 | 11/20 | 0.65 |
| ▸ | CDK2 | P24941 | 10/20 | 0.65 |
| ▸ | CDK9 | P50750 | 10/20 | 0.65 |
| ▸ | CCNB1 | P14635 | 9/20 | 0.65 |
| ▸ | CCNT1 | O60563 | 8/20 | 0.65 |
| ▸ | CCNB2 | O95067 | 7/20 | 0.65 |
| ▸ | CCNB3 | Q8WWL7 | 7/20 | 0.65 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.65 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.65 |
| ▸ | GSK3A | P49840 | 4/20 | 0.65 |
| ▸ | CDK7 | P50613 | 3/20 | 0.65 |
| ▸ | CCND3 | P30281 | 3/20 | 0.65 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.65 |
| ▸ | CCNH | P51946 | 2/20 | 0.65 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.65 |
| ▸ | MAPK15 | Q8TD08 | 2/20 | 0.65 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.65 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL665647 | 0.99 | CDK4 (0.66) | CDK4CDK1CCND1CDK2CDK9 | |
| SCHEMBL14694365 | 0.88 | CDK2 (0.53) | CDK4CDK1CCND1CDK2CDK9 | |
| SCHEMBL3108179 | 0.87 | CDK2 (0.51) | CDK4CDK1CCND1CDK2CDK9 | |
| Hydrochloric Acid SCHEMBL3119657 | 0.86 | CDK4 (0.51) | CDK4CDK1CCND1CDK2CDK9 | |
| SCHEMBL2446327 | 0.86 | CDK4 (0.68) | CDK4CDK1CCND1CDK2CDK9 | |
| SCHEMBL30688746 | 0.86 | CDK4 (0.68) | CDK4CDK1CCND1CDK2CDK9 | |
| Hydrochloric Acid SCHEMBL31632765 | 0.85 | CDK4 (0.67) | CDK4CDK1CCND1CDK2CDK9 | |
| Hydrochloric Acid SCHEMBL4015958 | 0.85 | CDK4 (0.67) | CDK4CDK1CCND1CDK2CDK9 | |
| Hydrochloric Acid SCHEMBL30688749 | 0.85 | CDK4 (0.67) | CDK4CDK1CCND1CDK2CDK9 | |
| SCHEMBL23788690 | 0.85 | CDK4 (0.67) | CDK4CDK1CCND1CDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383530-B2 | Pharmaceutical combination for the treatment of melanoma | Piramal Enterprises Limited (IN) | 2025-08-12 | — | — | US | disclosed |
| US-20240165076-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | Piramal Enterprises Limited (IN) | 2024-05-23 | — | — | US | disclosed |
| US-11839591-B2 | Pharmaceutical combination for the treatment of melanoma | Piramal Enterprises Limited (IN) | 2023-12-12 | — | — | US | disclosed |
| US-20210393589-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | Piramal Enterprises Limited (IN) | 2021-12-23 | — | — | US | disclosed |
| US-11007174-B2 | Pharmaceutical combination for the treatment of melanoma | Piramal Enterprises Limited (IN) | 2021-05-18 | — | — | US | disclosed |
| US-20190282544-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | Piramal Enterprises Limited (IN) | 2019-09-19 | — | — | US | disclosed |
| EP-3019166-B1 | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | PIRAMAL ENTPR LTD (IN) | 2019-05-08 | — | — | EP | disclosed |
| EP-2427188-B1 | PYRROLIDINE-SUBSTITUTED FLAVONES AS RADIO-SENSITIZERS FOR USE IN THE TREATMENT OF CANCER | PIRAMAL ENTPR LTD (IN) | 2016-08-10 | — | — | EP | disclosed |
| US-20160136132-A1 | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | Piramal Enterprises Limited (IN) | 2016-05-19 | — | — | US | disclosed |
| US-8895605-B2 | Pyrrolidine-substituted flavones as radio-sensitizers for use in the treatment of cancer | Piramal Enterprises Limited (IN) | 2014-11-25 | — | — | US | disclosed |
| EP-2802323-A1 | PYRROLIDINE- SUBSTITUTED FLAVONE DERIVATIVES FOR PREVENTION OR TREATMENT OF ORAL MUCOSITIS | Piramal Enterprises Limited (IN) | 2014-11-19 | — | — | EP | disclosed |
| WO-2014140695-A1 | SOLID ORAL FORMULATION OF A PYRROLIDINE SUBSTITUTED FLAVONE COMPOUND | Piramal Enterprises Limited (IN) | 2014-09-18 | — | — | WO | disclosed |
| WO-2013105056-A1 | PYRROLIDINE- SUBSTITUTED FLAVONE DERIVATIVES FOR PREVENTION OR TREATMENT OF ORAL MUCOSITIS | Piramal Enterprises Limited (IN) | 2013-07-18 | — | — | WO | disclosed |
| US-20120046334-A1 | PYRROLIDINE-SUBSTITUTED FLAVONES AS RADIO-SENSITIZERS FOR USE IN THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383530-B2 | Pharmaceutical combination for the treatment of melanoma | BRAF, CCNI, CDK1 | CDK4 4/4885CDK1 3/4885CCND1 55/4885 |
| US-20160136132-A1 | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | BRAF, CDK1, CCNI | CDK4 4/4885CDK1 2/4885CCND1 57/4885 |
| US-20120046334-A1 | PYRROLIDINE-SUBSTITUTED FLAVONES AS RADIO-SENSITIZERS FOR USE IN THE TREATMENT OF CANCER | CCNI, CCNK, CDK3 | CDK4 21/4885CDK1 13/4885CCND1 10/4885 |
| US-11839591-B2 | Pharmaceutical combination for the treatment of melanoma | BRAF, CCNI, CDK1 | CDK4 4/4885CDK1 3/4885CCND1 55/4885 |
| US-20190282544-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | BRAF, CCNI, CDK1 | CDK4 4/4885CDK1 3/4885CCND1 55/4885 |
| US-11007174-B2 | Pharmaceutical combination for the treatment of melanoma | BRAF, CCNI, CDK1 | CDK4 4/4885CDK1 3/4885CCND1 55/4885 |
| US-20210393589-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | BRAF, CCNI, CDK1 | CDK4 4/4885CDK1 3/4885CCND1 55/4885 |
| US-20240165076-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | BRAF, CDK1, CDK6 | CDK4 15/4885CDK1 2/4885CCND1 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.